Ulrik Lassen provides an overview of the frequency and distribution of NTRK gene fusions in rare and common human cancers, in particular very high occurrences in some rare cancers where their detection is also a part of diagnostic work-up and a low rate in some frequent cancers. Recent approvals of effective drugs might lead to the change in molecular testing mode: switching from time consuming and costly individual gene fusions detection to NGS.

Major Sponsors

AstraZeneca Bristol-Myers Squibb MSD Servier

Main Sponsors

Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo ipsen Janssen logo Pfizer Oncology Roche